AstraZeneca: strong sales growth in Q1

(CercleFinance.com) - AstraZeneca reports total sales of $12,679m for Q1, up 17% y-o-y (or +19% at constant exchange rates).


Pre-tax earnings came to $2,800m, up 24% (+34% at constant exchange rates).

The Anglo-Swedish laboratory reported adjusted quarterly EPS of $1.41, up 21% (+30% at constant exchange rates) on Q1 2023. Core EPS came to $2.06, up 7% (+13% at constant exchange rates).

Management also highlighted the positive and "unprecedented" trial results obtained for Imfinzi and Tagrisso in lung cancer.

It also looks forward to seeing the results of several other important trial projects throughout the year.

Against this backdrop, AstraZeneca will announce a 7% increase in the annual dividend at its AGM.

For 2024, AstraZeneca confirms its targets, with total sales and core EPS expected to rise by around 10% to 14%.


Copyright (c) 2024 CercleFinance.com. All rights reserved.